摘要
目的探究慢性收缩性心力衰竭患者采用伊伐布雷定治疗的临床效果及对超声心动图指标、血浆N末端钠尿肽前体的影响。方法将109例慢性收缩性心力衰竭患者随机分为两组,对照组给予常规药物治疗,观察组在对照组基础上增加伊伐布雷定治疗,对比两组的临床疗效、超声心动图指标、N末端钠尿肽前体(NT-proBNP)、血清降钙素原(PCT)、C反应蛋白(CRP)水平、药物安全性。结果治疗后观察组的临床疗效、LVEF水平显著高于对照组,观察组的IVS、LVPWT、LVEDD、LAD、CRP、PCT、NT-proBNP水平低于对照组,(p<0.05),观察组的不良反应发生率与对照组比较没有统计学意义(p>0.05)。结论伊伐布雷定治疗对慢性收缩性心力衰竭患者具有显著的治疗效果,可以有效维护患者的心室结构,同时明显降低患者的血清生化指标,具有较高的药物安全性。
Objective To explore the clinical effect of ivabradine treatment in patients with chronic systolic heart failure and its influence on echocardiographic indexes and plasma N-terminal natriuretic peptide precursor.Methods 109 patients with chronic systolic heart failure were randomly divided into two groups.The control group was given conventional drug treatment,and the observation group was treated with ivabradine on the basis of the control group.The clinical efficacy of the two groups was compared with echocardiographic indicators.N Terminal natriuretic peptide precursor(NT-proBNP),serum calcitonin(PCT),C-reactive protein(CRP)levels,and drug safety.Results After treatment,the clinical curative effect.LVEF level of the observation group was significantly higher than that of the control group.The IVS,LVPWT,LVEDD,LAD,CRP and PCT.NT-proBNP levels of the observation group were lower than those of the control group(p<0.05),The incidence of adverse reactions was not statistically significant compared with the control group(p>0.05).Conclusions Ivabradine treatment has a significant therapeutic effect on patients with chronic systolic heart failure.It can effectively maintain the patient’s ventricular structure,while significantly reducing the patient’s serum biochemical indicators,and has a high drug safety.
作者
孟腾腾
郝修宏
Meng tengteng;Hao xiuhong(Department of Cardiovascular Medicine,Third People's Hospital of Shangqiu City,Shangqiu,Henan,467000,China;Department of Cardiovascular Medicine,The First People's Hospital of Shangqiu City,Shangqiu,Henan,467000,China)
出处
《临床心电学杂志》
2021年第3期199-202,共4页
Journal of Clinical Electrocardiology
